AltPep develops early disease-modifying treatments and detection tools for amyloid diseases.
Our lead programs aim to identify Alzheimer’s disease and Parkinson’s disease long before symptoms occur and then neutralize toxic soluble oligomers associated with these diseases.
The AltPep platform, the foundation of our diagnostic and therapeutic programs, is based on a library of custom designed synthetic peptides. This growing library is being used to target one of the earliest molecular triggers of amyloid diseases.
Highly sensitive, simple blood tests in development to aid in the early detection of amyloid diseases.
In development for use in concert with early detection to target and neutralize the toxic soluble oligomers associated with amyloid diseases.
Recent News and Events
WSJ, July 13th, 2023
“… Similarly, AltPep, a Seattle-based biotech startup that recently raised $52.9 million venture financing is developing synthetic peptides designed to selectively bind to toxic oligomers. AltPep is developing a compound similar to its drug that would be used as a diagnostic to identify people with toxic oligomers.”
AltPep Corporation Announces Close of $53 Million Series B Financing to Advance Its Novel Therapeutics for both Alzheimer’s and Parkinson’s Diseases into the Clinic
Business Wire, June 22, 2023
AltPep Corporation, a privately-held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the completion of a $52.9 million Series B financing round. The financing was led by Senator Investment Group, LP, with participation from new financial investors, Section 32, Korea-based Partners Investment, and Eli Lilly and Company. Investors in AltPep’s Series A, including Alexandria Venture Investments and Matrix Capital Management Company, LP, also participated in the Series B.
GeekWire, May 18, 2023
AltPep has won the 2023 GeekWire Awards for Health Innovation of the Year! Click below to see the GeekWire Article and the other Award winners!
GeekWire, March 24, 2023
AltPep has been named among the finalists in the 2023 GeekWire Awards for Health Innovation of the Year! Click below to see the GeekWire Article and to vote for the AltPep team!
Public voting will run through May 1, and winners will be announced live on-stage at the GeekWire Awards on May 18!
AltPep Strengthens Advisory Board with Three Leading Experts in Alzheimer’s Disease and Neurodegenerative Disorders
Business Wire, February 9, 2023
AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the appointment of three new Advisory Board members: Paul Aisen, M.D., Sam Gandy, M.D., Ph.D., and Charlie Glabe, Ph.D. The advisory board now consists of world-renowned experts in discovery, preclinical and clinical research in Alzheimer’s disease and other neurodegenerative disorders…
National Institutes of Health, January 10, 2023
One of the first stages of Alzheimer’s disease involves formation of toxic aggregates, called oligomers, of the protein amyloid beta (Aβ). These oligomers can start to form more than a decade before symptoms appear and before other known disease markers form. The ability to detect these oligomers would permit early disease diagnosis. This would make strategies to intervene before irreparable brain damage occurs possible…
Alzforum, December 22, 2022
Before Aβ snaps into the rigid amyloid fibrils that predominate in plaques, the peptide clumps into soluble oligomers. Deemed the most toxic form of Aβ, these fledgling aggregates have also been devilishly difficult to detect. Now, researchers led by Valerie Daggett at the University of Washington in Seattle report that a soluble-oligomer binding assay—SOBA—picks them up in plasma, distinguishing controls and people with Alzheimer’s disease with 99 percent accuracy. The assay uses a designer peptide to capture oligomers that fold into α-sheets, a secondary structure that forms in the earliest stages of oligomerization…
Research Article. SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers
Proceedings of the National Academy of Sciences (PNAS), December 9, 2022
The formation of toxic Amyloid β-peptide (Aβ) oligomers is one of the earliest events in the molecular pathology of Alzheimer’s Disease (AD). These oligomers lead to a variety of downstream effects, including impaired neuronal signaling, neuroinflammation, tau phosphorylation, and neurodegeneration, and it is estimated that these events begin 10 to 20 y before the presentation of symptoms…
Bloomberg, December 5, 2022
A simple blood test that can detect Alzheimer’s disease years before symptoms appear may be one step closer to reality, as researchers devise a new method to find it early. The latest test focuses on amyloid beta proteins that have misfolded and are starting to clump together in the brain, a hallmark of Alzheimer’s disease. At one time, they could only be found during an autopsy. Now they are often uncovered with advanced imaging…
A New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selectively Detect and Neutralize an Early Molecular Trigger of Alzheimer’s and Other Neurodegenerative Diseases
Business Wire, December 5, 2022
AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that this week the Proceedings of the National Academy of Sciences (PNAS) will publish results of a groundbreaking study demonstrating a customized, synthetic peptide’s ability to selectively detect Alzheimer’s disease…